Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score
- PMID: 33503489
- DOI: 10.1016/j.jhep.2020.12.033
Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score
Abstract
Background & aims: In acute severe autoimmune hepatitis (AS-AIH), the optimal timing for liver transplantation (LT) remains controversial. The objectives of this study were to determine early predictive factors for a non-response to corticosteroids and to propose a score to identify patients in whom LT is urgently indicated.
Methods: This was a retrospective, multicenter study (2009-2016). A diagnosis of AS-AIH was based on: i) Definite or probable AIH based on the simplified IAIHG score; ii) international normalized ratio (INR) ≥1.5 and/or bilirubin >200 μmol/L; iii) No previous history of AIH; iv) Histologically proven AIH. A treatment response was defined as LT-free survival at 90 days. The evolution of variables from corticosteroid initiation (day-D0) to D3 was estimated from: Δ%3 = (D3-D0)/D0.
Results: A total of 128 patients were included, with a median age of 52 (39-62) years; 72% were female. Overall survival reached 88%. One hundred and fifteen (90%) patients received corticosteroids, with a LT-free survival rate of 66% at 90 days. Under multivariate analysis, D0-INR (odds ratio [OR] 6.85; 95% CI 2.23-21.06; p <0.001), Δ%3-INR ≥0.1% (OR 6.97; 95% CI 1.59-30.46; p <0.01) and Δ%3-bilirubin ≥-8% (OR 5.14; 95% CI 1.09-24.28; p <0.04) were predictive of a non-response. The SURFASA score: -6.80+1.92∗(D0-INR)+1.94∗(Δ%3-INR)+1.64∗(Δ%3-bilirubin), created by combining these variables, was highly predictive of LT or death (AUC = 0.93) (88% specificity; 84% sensitivity) with a cut-off point of <-0.9. Below this cut-off, the chance of responding was 75%. With a score higher than 1.75, the risk of dying or being transplanted was between 85% and 100%.
Conclusion: In patients with AS-AIH, INR at the introduction of corticosteroids and the evolution of INR and bilirubin are predictive of LT or death. Within 3 days of initiating corticosteroids, the SURFASA score can identify non-responders who require a referral for LT. This score needs to be validated in a prospective cohort.
Lay summary: The management of patients with acute severe autoimmune hepatitis is highly challenging, particularly regarding their early referral for liver transplantation. We found that international normalized ratio at the initiation of corticosteroid therapy and the evolution of international normalized ratio and bilirubin values after 3 days of therapy were highly predictive of liver transplantation or death. We are thus proposing a score that combines these variables and identifies patients in whom liver transplantation is urgently required.
Keywords: autoimmune hepatitis; corticosteroid therapy; liver transplantation; prognostic score; severe acute hepatitis.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest EDM: nothing to disclose, AC: nothing to disclose, OC: nothing to disclose, OR: nothing to disclose, JMP: nothing to disclose, PHD: nothing to disclose, FA: nothing to disclose, CS: nothing to disclose, IOH: nothing to disclose, CD: nothing to disclose, AHB: nothing to disclose, SB: nothing to disclose, NG: nothing to disclose, GPP: nothing to disclose, CB: nothing to disclose, MB: nothing to disclose, HF: nothing to disclose, VdL: nothing to disclose, JD: nothing to disclose, FC: nothing to disclose, SR: nothing to disclose, MDG: nothing to disclose, OG: nothing to disclose, FD: nothing to disclose, PP: nothing to disclose, VDM: nothing to disclose, NR: nothing to disclose, PI: nothing to disclose, MS: nothing to disclose, PM: nothing to disclose, HA: nothing to disclose, DS: nothing to disclose, JCDV: nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents.J Hepatol. 2021 Aug;75(2):494-495. doi: 10.1016/j.jhep.2021.03.031. Epub 2021 Apr 30. J Hepatol. 2021. PMID: 33933562 No abstract available.
-
Reply to: "Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents".J Hepatol. 2021 Aug;75(2):495-496. doi: 10.1016/j.jhep.2021.05.010. Epub 2021 May 27. J Hepatol. 2021. PMID: 34051331 No abstract available.
-
Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis.J Hepatol. 2022 Feb;76(2):485-487. doi: 10.1016/j.jhep.2021.08.013. Epub 2021 Aug 25. J Hepatol. 2022. PMID: 34453964 No abstract available.
-
Reply to: "Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis".J Hepatol. 2022 Feb;76(2):487-488. doi: 10.1016/j.jhep.2021.11.002. Epub 2021 Nov 10. J Hepatol. 2022. PMID: 34774640 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
